The half-life of CJC-1295 no DAC is about 30 minutes, far shorter than the DAC version. Learn how this affects dosing, timing, and research use.
The half-life of CJC-1295 no DAC is approximately 30 minutes in human plasma, with most estimates ranging from 25 to 30 minutes. This short duration is the key difference between CJC-1295 no DAC and CJC-1295 with DAC, which remains active for 6 to 8 days. Because the no-DAC version clears quickly, research protocols typically involve more frequent injections to maintain growth hormone release.
What Is CJC-1295 No DAC?
CJC-1295 no DAC is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH). It is also known as Mod GRF 1-29, a modified form of GRF 1-29 that resists enzymatic breakdown slightly better than the natural hormone. The "no DAC" label means the peptide lacks the Drug Affinity Complex, a chemical modification that binds the molecule to albumin in the bloodstream.
Without the DAC group, the peptide is free to be broken down by enzymes called dipeptidyl peptidase IV (DPP-IV) and other proteases. This rapid breakdown is the main reason for its short half-life. Researchers use CJC-1295 no DAC to study pulsatile growth hormone release, which more closely resembles the body's natural rhythm.
Half-Life Comparison: No DAC vs. DAC
The table below summarizes the key differences between the two forms of CJC-1295. The half-life of cjc-1295 no dac is measured in minutes, while the DAC version is measured in days.
| Feature | CJC-1295 No DAC (Mod GRF 1-29) | CJC-1295 With DAC |
|---|---|---|
| Half-life | ~30 minutes (25–30 min) | 6–8 days |
| Albumin binding | No | Yes |
| Typical dosing frequency | 2–3 times daily | Once weekly or less |
| Growth hormone release pattern | Rapid, short-lived pulses | Sustained, prolonged elevation |
| Also known as | Mod GRF 1-29 | CJC-1295 DAC |
The cjc-1295 no dac half-life is short because the peptide is quickly degraded by enzymes in the blood and tissues. In contrast, the cjc 1295 dac half life is long because the Drug Affinity Complex attaches to albumin, a protein that protects the peptide from breakdown and slowly releases it over time.
This difference means that the two versions are not interchangeable in research. A scientist studying acute growth hormone pulses would choose the no-DAC form, while one studying sustained elevation would use the DAC form.
Why the Short Half-Life Matters for Dosing
Because CJC-1295 no DAC is cleared within about half an hour, a single injection produces a brief spike in growth hormone. To maintain elevated levels, researchers often administer the peptide multiple times per day. A common research cjc-1295 no dac dosage is 100 to 200 micrograms per injection, given two or three times daily, though exact protocols vary.
The short half-life also influences the benefits of cjc 1295 no dac that researchers investigate. These may include a more natural, pulsatile release of growth hormone compared to the continuous stimulation from the DAC version. Some studies suggest that pulsatile release is important for normal growth and metabolism.
Timing injections around natural growth hormone peaks—such as before sleep or after exercise—is a common strategy in research settings. However, the optimal timing for CJC-1295 no DAC has not been established in large human trials.
Factors That Can Affect the Half-Life
The reported half-life of 30 minutes is an average from limited studies. Individual factors can change how long the peptide stays active in the body.
- Metabolism: People with faster enzyme activity may clear the peptide more quickly.
- Injection site: Subcutaneous injections may absorb differently than intramuscular ones.
- Formulation: The presence of preservatives or carriers can slightly alter stability.
- Body composition: Higher body fat may affect absorption and distribution.
These factors mean that the exact half-life can vary from person to person. Researchers should rely on published pharmacokinetic data when designing studies, not on personal anecdotes.
Safety and Legal Status
CJC-1295 no DAC is not approved by the FDA for human use in the United States. It is sold as a research chemical, and its safety and efficacy have not been established in large clinical trials. Potential side effects reported in anecdotal accounts include injection site reactions, headaches, and changes in blood sugar.
Anyone considering the use of CJC-1295 no DAC should consult a healthcare professional. Self-administering research peptides carries legal and health risks. The long-term effects of growth hormone stimulation are not fully understood, and unregulated products may contain impurities.
In summary, the half-life of CJC-1295 no DAC is roughly 30 minutes, which is much shorter than the 6- to 8-day half-life of the DAC version. This short duration drives the need for frequent dosing and makes the no-DAC peptide better suited for research on pulsatile growth hormone release. Always prioritize safety and consult a qualified professional before using any peptide.
Frequently Asked Questions
How long does CJC-1295 no DAC stay in your system?
The half-life of CJC-1295 no DAC is about 30 minutes, so it is largely cleared from the bloodstream within a few hours. Most research protocols assume the peptide is active for roughly 1 to 2 hours after injection. This is much shorter than CJC-1295 with DAC, which stays active for 6 to 8 days.
What is the difference between CJC-1295 no DAC and CJC-1295 with DAC?
CJC-1295 no DAC lacks the Drug Affinity Complex that binds the peptide to albumin, so it has a half-life of about 30 minutes. CJC-1295 with DAC includes that complex and has a half-life of 6 to 8 days. The no-DAC version is also known as Mod GRF 1-29.
What is a typical CJC-1295 no DAC dosage?
In research settings, CJC-1295 no DAC is often dosed at 100 to 200 micrograms per injection, two or three times daily. However, there is no FDA-approved human dosage, and these amounts come from anecdotal reports and limited studies. Always consult a healthcare professional before using any research peptide.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.